Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: C-Met-dependent tumors in animal models

Molecular Cancer Therapeutics

Volumn 8, Issue 5, 2009, Pages 1119-1125

  Coxon, Angela ^a   Rex, Karen ^a   Meyer, Susanne ^a   Sun, Jianling ^a   Sun, Jilin ^a   Chen, Qing ^a   Radinsky, Robert ^a   Kendall, Richard ^a   Burgess, Teresa L ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT SCATTER FACTOR RECEPTOR FUSION PROTEIN; IMMUNOGLOBULIN G1; SCATTER FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SURFACE PLASMON RESONANCE; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CRICETINAE; FEMALE; HEK293 CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MET; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66849132233     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1032     Document Type: Article

References (43)

1. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 1993;123:223-235 (Pubitemid 23284877)
2. Bharti S, Handrow-Metzmacher H, Zickenheiner S, Zeitvogel A, Baumann R, Starzinski-Powitz A. Novel membrane protein shrew-1 targets to cadherin-mediated junctions in polarized epithelial cells. Mol Biol Cell 2004;15:397-406. (Pubitemid 38044972)
3. Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Curr Mol Med 2004;4:855-868 (Pubitemid 39585731)
4. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-1488 (Pubitemid 40270177)
5. Natali PG, Prat M, Nicotra MR, et al. Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer 1996;69:212-217 (Pubitemid 26233301)
6. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73. (Pubitemid 27198158)
7. Siegfried JM, Weissfeld LA, Luketich JD, Weyant RJ, Gubish CT, Landreneau RJ. The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg 1998;66:1915-1918 (Pubitemid 29087181)
8. Giordano S, Maffe A, Williams TA, et al. Different point mutations in the met oncogene elicit distinct biological properties. Faseb J 2000;14:399-406. (Pubitemid 30086077)
9. Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S, Vande Woude GF. The mutationally a ctivated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A 1998;95:14417-14422 (Pubitemid 28549382)
10. Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 1997;94:11445-11450 (Pubitemid 27451018)
11. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18:2343-2350 (Pubitemid 29192711)
12. Olivero M, Valente G, Bardelli A, et al. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer 1999;82:640-643 (Pubitemid 29356960)
13. Michieli P, Basilico C, Pennacchietti S, et al. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 1999;18:5221-5231 (Pubitemid 29460658)
14. Graveel C, Su Y, Koeman J, et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A 2004;101:17198-17203 (Pubitemid 39627797)
15. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activityin invasive tumors. J Clin Invest 2002;109:863-867 (Pubitemid 34275106)
16. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13:41-59. (Pubitemid 34436961)
17. Zhang YW, Su Y, Lanning N, et al. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 2005;24:101-106 (Pubitemid 40143869)
18. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997;420:1-6. (Pubitemid 28037188)
19. Tomioka D, Maehara N, Kuba K, et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 2001;61:7518-7524 (Pubitemid 32995042)
20. Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessaryf or receptor dimerization and activation. Cancer Cell 2004;6:75-84. (Pubitemid 38903163)
21. Mark MR, Lokker NA, Zioncheck TF, Luis EA, Godowski PJ. Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins. Effects of mutations in the potential proteolytic cleavage site on processing and ligand binding. J Biol Chem 1992;267:26166-26171 (Pubitemid 23014031)
22. Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment bya dual-function decoy Met receptor. Cancer Cell 2004;6:61-73. (Pubitemid 38903162)
23. Tiran Z, Oren A, Hermesh C, et al. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway. Clin Cancer Res 2008;14:4612-4621
24. Albrecht BK, Harmange JC, Bauer D, et al. Discoveryand optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem 2008;51:2879-2882
25. Bellon SF, Kaplan-Lefko P, Yang Y, et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 2008;283:2675-2683
26. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-7355 (Pubitemid 37413476)
27. Sattler M, Pride YB, Ma P, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003;63:5462-5469 (Pubitemid 37139865)
28. Wang X, Le P, Liang C, et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther 2003;2:1085-1092
29. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006;66:1721-1729 (Pubitemid 43259957)
30. Cao B, Su Y, Oskarsson M, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A 2001;98:7443-7448 (Pubitemid 32567968)
31. Kim CH, Moon SK, Bae JH, et al. Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol 2006;126:88-94. (Pubitemid 41769745)
32. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007;13:6735-6742 (Pubitemid 350206811)
33. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:6144-6152 (Pubitemid 44703780)
34. Coxon A, Rex K, Sun J, et al. Exploratory biomarkers in the HGF/SF:c-Met axis: preclinical and clinical results. American Association for Cancer Research, San Diego April 12 to 16, 2008 Abstract #2804.
35. Gordon MS, Mendelson DS, Sweeney C, et al. Interim results from a first-in-human study with AMG 102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors. J Clin Oncol 2007;25:Abstract #3551.
36. Reardon DA, Cloughsey TF, Raizer JJ, et al. Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. J Clin Oncol 2008;26:Abstract #2051.
37. Rosen PJ, Sweeney CJ, Park DJ, et al. AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors. J Clin Oncol 2006;26:Abstract #3570.
38. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-516
39. Edakuni G, Sasatomi E, Satoh T, Tokunaga O, Miyazaki K. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int 2001;51:172-178 (Pubitemid 32337066)
40. Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008;18:87-96.
41. Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer 2008;44:641-651
42. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathwayin cancer. Clin Cancer Res 2006;12:3657-3660 (Pubitemid 44000247)
43. Tuck AB, Park M, Sterns EE, Boag A, Elliott BE. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 1996;148:225-232 (Pubitemid 26022451)